Page 2 - Parsortix System Enables News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Parsortix system enables. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Parsortix System Enables Today - Breaking & Trending Today

ANGLE plc: Angle PLC Announces Concordance of Parsortix with tissue biopsy

BREAKTHROUGH STUDY DEMONSTRATES FOR THE FIRST TIME CONCORDANCE OF PARSORTIX LIQUID BIOPSY BLOOD TEST WITH INVASIVE TISSUE BIOPSY OF THE METASTATIC SITEStudy explores key unmet medical need for metastatic ....

United States , Western Australia , United Kingdom , City Of , Andrew Newland , Julie Lang , London Stock Exchange , Laboratory Developed Tests Ldts , University Of Southern California , University Of Southern California Norris Cancer Center , Breast Cancer Program , Norris Comprehensive Cancer Center , Company Parsortix , National Comprehensive Cancer Network , Southern California Norris Cancer , Surgical Oncology , Breast Surgery , Comprehensive Breast Cancer Program , Cleveland Clinic Cancer Center , Cancer Program , Associate Professor , Southern California , Chief Executive , Frequently Used Terms , Key Opinion Leaders , Laboratory Developed Tests ,

ANGLE plc: Angle Plc - Announces Parsortix: Dynamic Assessment of Patient Response

ANGLE plc: Angle Plc - Announces Parsortix: Dynamic Assessment of Patient Response
Use of Parsortix System Enables a Dynamic Assessment of Patient Response to Treatment in Non-Small Cell Lung Cancer
CTCs harvested by the Parsortix system successfully used to measure the dynamic role of EMT and PD-L1 in patient response to therapy
Findings support ANGLE s plan for the growth of a new pharma services business area using the Parsortix system as a biomarker for cancer drug trials allowing longitudinal monitoring of patients
GUILDFORD, SURREY / ACCESSWIRE / February 8, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the National and Kapodistrian University of Athens (Athens) has published results of a new study undertaken in non-small cell lung cancer (NSCLC). This study demonstrates the utility of ANGLE s Parsortix ....

United States , United Kingdom , City Of , Carl Holmes , Ciara Martin , Simon Hicks , Teddy Whiley , Andrew Craig , Andrew Newland , Nigel Barnes , Nigel Birks , Ian Griffiths , Osimertinib Astrazeneca Tagrisso , Simon Conway , Chris Lee , London Stock Exchange , Kapodistrian University Of Athens , Department Of Chemistry , Cap Ltd , Head Of The Molecular Diagnostics Laboratory , American Cancer Society , Parsortix System Enables , Dynamic Assessment , Patient Response , Non Small Cell Lung Cancer , Kapodistrian University ,

ANGLE plc: Angle PLC - Parsortix Demonstrates High Capture Rate of CTCs

ANGLE plc: Angle PLC - Parsortix Demonstrates High Capture Rate of CTCs
Parsortix system demonstrates high capture rate of CTCs irrespective of biomarker status or phenotype
GUILDFORD, SURREY / ACCESSWIRE / January 29, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the publication of a five year programme of work undertaken by the CANCER-ID Consortium to establish the performance and technical capabilities of five circulating tumour cell (CTC) isolation platforms, in which key advantages of the Parsortix
® system were identified. The CANCER-ID consortium is supported by Europe s Innovative Medicines Initiative (IMI) and is a Europe-wide Public-Private-Partnership aimed at the establishment of standard protocols for, and clinical validation of, blood-based biomarkers in order to drive wide adoption of liquid biopsy in clinical practice and pharma services. ....

United States , Western Australia , City Of , United Kingdom , Nikolas Stoecklein , Carl Holmes , Ciara Martin , Simon Hicks , Teddy Whiley , Andrew Craig , Andrew Newland , Nigel Barnes , Nigel Birks , Ian Griffiths , Simon Conway , Chris Lee , London Stock Exchange , European Liquid Biopsy Society , Enterprises Smes , Innovative Medicines Initiative , Cap Ltd , Europe Innovative Medicines Initiative , Europe Wide Public Private Partnership , Clinical Chemistry , Experimental Surgical Oncology , Heinrich Heine University ,